Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
SHEZF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $1,423,097 | $1,394,250 | $1,211,789 | $1,231,523 |
| % Growth | 2.1% | 15.1% | -1.6% | – |
| Cost of Goods Sold | $926,290 | $1,013,068 | $806,633 | $868,780 |
| Gross Profit | $496,807 | $381,182 | $405,156 | $362,743 |
| % Margin | 34.9% | 27.3% | 33.4% | 29.5% |
| R&D Expenses | $62,723 | $39,994 | $82,059 | $48,936 |
| G&A Expenses | -$40,966 | $97,733 | -$163,686 | $234,526 |
| SG&A Expenses | $14,284 | $191,203 | -$135,311 | $361,211 |
| Sales & Mktg Exp. | $55,250 | $93,470 | $28,376 | $126,685 |
| Other Operating Expenses | $114,522 | -$28,995 | $620,575 | -$167,540 |
| Operating Expenses | $191,529 | $202,201 | $567,323 | $242,607 |
| Operating Income | $305,278 | $178,980 | -$162,167 | $120,136 |
| % Margin | 21.5% | 12.8% | -13.4% | 9.8% |
| Other Income/Exp. Net | $125 | -$741 | $1,193 | -$582 |
| Pre-Tax Income | $305,403 | $178,239 | -$160,974 | $119,554 |
| Tax Expense | $40,392 | $22,070 | -$6,832 | $3,330 |
| Net Income | $265,260 | $156,590 | -$133,372 | $116,430 |
| % Margin | 18.6% | 11.2% | -11% | 9.5% |
| EPS | 0.18 | 0.11 | -0.091 | 0.079 |
| % Growth | 63.6% | 221% | -214.5% | – |
| EPS Diluted | 0.18 | 0.11 | -0.091 | 0.079 |
| Weighted Avg Shares Out | 1,467,574 | 1,467,574 | 1,467,296 | 1,467,296 |
| Weighted Avg Shares Out Dil | 1,467,574 | 1,467,574 | 1,467,296 | 1,467,296 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,141 | $9,254 | $11,085 | $14,693 |
| Interest Expense | $17,529 | $22,447 | $30,638 | $30,990 |
| Depreciation & Amortization | $0 | $0 | $0 | $30,407 |
| EBITDA | $322,932 | $200,686 | -$130,336 | $180,951 |
| % Margin | 22.7% | 14.4% | -10.8% | 14.7% |